PMID: 2507346Aug 1, 1989Paper

Oral cyclosporin-A is effective treatment for untreated and also for previously immunosuppressed patients with severe bone marrow failure

European Journal of Haematology
M Hinterberger-FischerW Hinterberger

Abstract

16 patients with transfusion-dependent, life-threatening bone marrow failure (14 with severe aplastic anaemia, 1 with systemic lupus erythematosus and 1 with pure red cell aplasia) were treated with cyclosporin-A (Cy-A) after either lack of response to conventional immunosuppression with antithymocyte-globulin/high-dose methylprednisolone for 95 to 1190 days (median 186.5) (group I, 8 patients) or as a primary treatment due to ineligibility for conventional immunosuppression (group II, 8 pat.). Cyclosporin-A was given orally to maintain trough levels of 200 to 300 ng/ml (RIA). In group I, 6 out of 8 patients responded 30 to 480 d (median 53) and are currently alive 627 to 1482 d (median 731) after initiation of Cy-A, respectively. In 3 of the responders Cy-A has been withdrawn, without relapse. In group II, 5 of 8 patients responded 26 to 170 d (median 63) and are currently alive 142 to 697 (median 420) d following initiation of Cy-A, respectively. These data indicate a place for cyclosporin-A in the management of patients with life-threatening bone marrow failure in whom a) immunosuppressive therapy with antithymocyte-globulin and high-dose methylprednisolone had failed and b) who are not candidates for vigorous immunosuppress...Continue Reading

References

Jan 1, 1988·British Journal of Haematology·A TichelliB Speck
Sep 1, 1987·American Journal of Hematology·R BridgesW Blahey
Jan 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·N C ZoumbosN S Young
Oct 1, 1985·British Journal of Haematology·P JacobsR W Martell
Jan 20, 1983·The New England Journal of Medicine·R ChamplinR P Gale
May 1, 1983·British Journal of Haematology·J M HowsE C Gordon-Smith
Mar 8, 1984·The New England Journal of Medicine·P A StryckmansL Debusscher

❮ Previous
Next ❯

Citations

Mar 1, 1991·American Journal of Hematology·J M CanvinJ B Johnston
Jul 1, 1992·Annals of Hematology·H SchrezenmeierA Raghavachar
Sep 19, 2003·Wiener klinische Wochenschrift·Klaus Geissler
Nov 8, 2005·Annals of Saudi Medicine·Jameel Al-GhazalyAdela Al-Hashdi
Sep 22, 2011·Onkologie·Philipp BaumannFuat S Oduncu
Oct 1, 1996·The Annals of Pharmacotherapy·C ColbyT R Spitzer
Jan 10, 2001·Bone Marrow Transplantation·M FouladiM H Freedman
Jan 29, 2008·International Journal of Hematology·Mamiko HattoriHaruhiko Ohashi
Dec 1, 2007·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Niranjan BiswalGinigeri Chetan
Mar 6, 1998·British Journal of Haematology·A TichelliA Gratwohl
Oct 14, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·C TagoeH M Belmont
Oct 31, 2014·Rheumatology International·Emilie ChalayerPascal Cathébras
Feb 6, 2018·Seminars in Arthritis and Rheumatism·Erik AndersonRichard Furie
Feb 17, 2000·Seminars in Hematology·J F TisdaleJ Maciejewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.